Product description
ODN-1018 is a Toll-like receptor 9 (TLR9)-targeting immunostimulatory oligonucleotide active pharmaceutical ingredient (API) and a next-generation Class C CpG oligodeoxynucleotide (CpG ODN) featuring balanced immune activation, broad applicability, and an excellent safety profile. Unlike conventional Class A or Class B CpG sequences with single-function activity, ODN-1018 simultaneously induces robust type I interferon production and pro-inflammatory cytokine expression while activating multiple immune cell populations, including dendritic cells and macrophages. This dual mechanism provides antiviral, antitumor, and adaptive immune-enhancing activities with comprehensive yet well-balanced immune stimulation, excellent biocompatibility, minimal risk of excessive immune activation, and broad application potential.
Manufactured using a proprietary precision chemical synthesis and backbone modification process, the product achieves a purity of ≥98%, with trace impurities strictly controlled in accordance with the highest industry quality standards. It demonstrates outstanding batch-to-batch consistency, excellent physicochemical stability, and uniform long-lasting biological activity, delivering superior quality compared with conventional CpG oligonucleotide materials.
Produced on standardized GMP-compliant manufacturing lines, the product can be supplied with a complete Certificate of Analysis (COA), comprehensive impurity profiles, and regulatory documentation to support research, process development, and large-scale manufacturing of universal vaccine adjuvants, broad-spectrum anti-infective immunotherapeutics, tumor immunostimulatory formulations, and immunomodulatory biologics.
ODN-1018 efficiently activates the TLR9 signaling pathway, coordinately regulates innate and adaptive immunity, enhances antiviral and antibacterial immune responses, promotes antitumor immune surveillance, and improves vaccine immunogenicity. It combines broad-spectrum immune activation, vaccine adjuvant enhancement, anti-infective immune support, and tumor immunotherapy assistance, making it a high-quality intermediate for the development of next-generation vaccines, broad-spectrum immunotherapeutics, and immunology research.
This product is intended solely for research use and as a biopharmaceutical intermediate and is not intended for direct human use.